


Pharmaceutical Dosage Forms: Parenteral Medications Volume 1

Second Edition, Revised and Expanded

Edited by Kenneth E. Avis,
Herbert A. Lieberman, and Leon Lachman



Pharmaceutical Dosage Forms: Parenteral Medications Volume 1

Second Edition, Revised and Expanded

Edited by

Kenneth E. Avis

*The University of Tennessee
Memphis, Tennessee*

Herbert A. Lieberman

*H.H. Lieberman Associates, Inc.
Consultant Services
Livingston, New Jersey*

Leon Lachman

*Lachman Consultant Services
Westbury, New York*



Marcel Dekker, Inc.

New York • Basel • Hong Kong

Library of Congress Cataloging - in - Publication Data

Pharmaceutical dosage forms, parenteral medications / edited by
Kenneth E. Avis, Herbert A. Lieberman, and Leon Lachman. -- 2nd ed.,
rev. and expanded.

p. cm.

Includes bibliographical references and index.

ISBN 0-8247-8576-2 (v. 1 : alk. paper)

1. Parenteral solutions. 2. Pharmaceutical technology. I. Avis,
Kenneth E. II. Lieberman, Herbert A.

III. Lachman, Leon.

[DNLM: 1. Infusions, Parenteral. 2. Technology, Pharmaceutical.

WB 354 P536]

RS201.P37P48 1992

615'. 19--dc20

DNLM/DLC

for Library of Congress

91 - 38063
CIP

This book is printed on acid-free paper.

Copyright © 1992 by MARCEL DEKKER, INC. All Rights Reserved

Neither this book nor any part may be reproduced or transmitted in any form
or by any means, electronic or mechanical, including photocopying, micro-
filming, and recording, or by any information storage and retrieval system,
without permission in writing from the publisher.

MARCEL DEKKER, INC.

270 Madison Avenue, New York, New York 10016

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

PRINTED IN THE UNITED STATES OF AMERICA

Preface

Since the publication in 1984 of the first edition of our two-volume, in-depth treatment of dosage forms for parenterals, many changes have occurred in the science and technology associated with these products. Consequently, to update and adequately cover the new subject matter devoted to parenteral medications, a three-volume set was deemed necessary. The new volumes cover topics not previously treated in the first edition; for example, genetically engineered injectable drugs and the ways in which they are prepared, sterile in vitro and in vivo diagnostic agents, the theory and practice of freeze drying, ophthalmic preparations, and validation and auditing procedures. The changes in FDA requirements for NDA and IND submissions and regulatory compliance considerations are discussed.

The topics covered in the first edition have been updated and, where necessary, expanded or rewritten, and some new authors have been added. The material in the three texts is covered with the intention of teaching both graduate and undergraduate students as well as of benefiting professionals practicing either industrial or hospital pharmacy, regulatory affairs personnel, and lawyers involved with medicinal products.

The new three-volume series is organized with the subject matter presented in three broad topical areas. Volume 1 contains chapters describing formulation and product development. Volume 2 deals with processing, and Volume 3 encompasses chapters related to quality assurance, devices, and regulatory matters. We hope this focused arrangement of subjects within each volume will facilitate and enhance the effective use of each of these books.

In Volume 1, Chapter 1, "The Parenteral Dosage Form and Its Historical Development," contains an updated version of an introduction to parenteral dosage forms and recent historical developments. Chapter 2, "Parenteral Drug Administration: Routes, Precautions, Problems, Complications, and Drug Delivery Systems," continues the thorough discussion of the administration of parenteral dosage forms, with the addition of a section on the new methods and devices for delivering drugs parenterally. Chapter 3, "Biopharmaceutics of Injectable Medications," has been expanded to include examples of biopharmaceutic/pharmacokinetic principles and to illustrate some of the variables and dynamics influencing drug absorption from parenteral sites. A new section that deals with regulatory considerations for parenteral bioequivalence is intended to provide the formulator with the basic steps required for the development of generic parenterals.

Chapter 4, "Preformulation Research of Parenteral Medications," now includes a section on the preformulation of proteins and polypeptides, a highly important topic today. These molecules are complex and can undergo physical and chemical changes markedly different from nonprotein substances. In addition, a section is included on the screening of devices used for administering drugs intravenously, since awareness is increasing that interactions between the product and the drug delivery device can result in a compromise of drug activity. Chapter 5, "Formulation of Small Volume Parenterals," includes recent work on the cyclodextrins as solubilizers as well as on the use of solubility parameters to enhance and protect solubility. Attention has been given to aluminum contamination and relevant concerns. The stability evaluation section has been revised to include updating of compendial requirements and the internationalization efforts to unify standards.

Chapter 6, "Formulation of Large Volume Parenterals," now includes an expanded discussion of the formulation of amino acid solutions and lipid emulsions. These additions allow a logical progression into a discussion of total parenteral nutrition (TPN), the solutions utilized, and additives as they affect the formulation scientist. Chapter 7, "Parenteral Products of Peptides and Proteins," is a new chapter reflecting the growing importance of these complex new drugs and their dosage forms. Various formulations of therapeutic proteins and peptides are presented, with emphasis on the stability parameters that must be evaluated and the various stabilizers that can be used to formulate a stable product. Formulation principles are illustrated with examples of recently developed protein and peptide products.

Chapter 8, "Sterile Diagnostics," is another new chapter. A general overview is given of the wide range of available diagnostic products, described by categories. This is followed by a discussion of sterile diagnostics, with an emphasis on their similarities and differences in comparison with sterile parenteral products and their processing. The preparation of human serum is elaborated as an example of a sterile diagnostic agent and its production. A final section gives a validation protocol for the aseptic filling and capping of cell culture tubes.

The next three chapters, Chapter 9, "Glass Containers for Parenterals," Chapter 10, "Use of Plastics for Parenteral Packaging," and Chapter 11, "Elastomeric Closures for Parenterals," all are extensively revised and updated. Chapter 9 introduces much more information on tubing-made containers and the controls utilized to assure their integrity of composition and physical uniformity. There is an expanded discussion of the current methods used to improve container interior-surface durability. The chapter also contains a new section on the container/closure as a system, giving the important factors necessary to insure proper functioning of these elements as an integral unit. Chapter 10 was rewritten by new authors and contains additional material on the properties of plastics and their selection for parenteral containers and other medical uses. A number of the more recent plastics, such as polysulfone and polymethylpentene, are included, and their properties are discussed. In this edition, Chapter 11 includes both thermoset and thermoplastic elastomers, some of which have the physical properties of elastomers yet offer the drug compatibility of most plastics. The new USP XXII biological tests are reviewed and the International Standards Organization (ISO) tests are fully explained and compared to the USP/NF tests used in the United States. Container/closure integrity evaluation using new test methods is also discussed.

Chapter 12, "Parenteral Products in Hospital Practice and Home Care Pharmacy Practice," has been updated and expanded to include the pharmaceutical control procedures used for parenteral products that are distributed in patient home care settings. Increased emphasis is also given to the assurance of quality in dispensing extemporaneously compounded and batch-processed sterile products.

Volume 2 contains revised chapters on the processing of small and large volume parenterals. A new chapter is included on the principles and practices in freeze drying, with formulation examples. The freeze drying process is being utilized increasingly for products that show significant instability except in the dry state, such as the new polypeptides and proteins. The chapter on the design of a parenteral production facility has been updated and a new chapter included on the distinctive characteristics of a facility for the processing of biopharmaceuticals. The chapter on personnel, their behavior requirements and their training, has been revised. Also, the chapter on controlling and monitoring the environment has been updated. The important chapter on industrial sterilization has been enlarged and updated. The final chapter is a new one concerning the formulation and development of ophthalmic preparations.

Volume 3 centers on quality assurance, devices, and regulatory matters. The first chapter is an updating of the chapter in the first edition on quality assurance. The second chapter is also a revision of the first-edition chapter dealing with records and reports. Particulate matter and its importance in parenterals is presented in the third chapter. A new chapter is introduced on validation principles and current philosophies in the manufacture of parenteral products. The chapter on federal regulations of parenterals has been updated. A new chapter is included on the audit process offering extensive insight into this highly important quality assurance procedure. The last three chapters in Volume 3 provide revised descriptions of devices, their design and manufacture, quality assurance, and GMP considerations.

As is evident from the content of these three volumes, the editors have attempted to broadly cover the subject matter concerned with parenteral medications by revising, updating, and adding new subject matter. Also, the editors strived to have each chapter be of comparable high quality in content and style, the first requirement for acceptance being that each chapter teach by clearly presenting the assigned subject.

The editors commend the resourcefulness and perseverance of the contributors to this volume for their efforts in completing their chapters despite the continued pressures placed on them by their regular jobs and other responsibilities. Each contributor, an expert in the field of the chosen topic, provides the readers with a strong technical basis to increase their understanding and broaden their knowledge in the chapter's subject matter. The editors are highly appreciative for the outstanding contributions by all of the authors.

Both the contributors and editors hope that this first volume of the three-volume set will provide essential knowledge and insight into the formulation and product development aspects of parenteral products. Further, the contributors and editors have aimed to provide a medium that will be helpful in solving problems involved with developing and maintaining superior parenteral medications.

Kenneth E. Avis
Herbert A. Lieberman
Leon Lachman

Contributors

R. Paul Abendroth, Ph.D. Manager, Laboratory Services Department, Kimble Glass, Inc., Vineland, New Jersey

Shreeram N. Agharkar, Ph.D. Director, Formulations R&D, Bristol-Myers Squibb Company, Syracuse, New York

Michael J. Akers, Ph.D. Manager, Corporate Quality Assurance, Eli Lilly and Company, Indianapolis, Indiana

John M. Anes Manager, New Product Development, The West Company, Phoenixville, Pennsylvania

Kenneth E. Avis, D.Sc. Emeritus Professor, Department of Pharmaceutics, The Health Science Center, The University of Tennessee, Memphis, Tennessee

James C. Boylan, Ph.D. Director, Scientific Affairs and Research & Development, Hospital Products Division, Abbott Laboratories, Abbott Park, Illinois

Robert N. Clark Group Leader, Chemical Development, Glass Container Engineering and Research, Owens-Brockway, Toledo, Ohio

Patrick P. DeLuca, Ph.D. Professor, University of Kentucky College of Pharmacy, Lexington, Kentucky

Levit J. Demorest, Ph.D.* Consultant, Quality Assurance Systems, Danville, California

Richard J. Duma, M.D., Ph.D. Chairman, Division of Infectious Diseases, Professor of Medicine, Pathology and Microbiology, Department of Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

Jeffrey G. Hamilton Division Director, Quality Assurance, Alliance Pharmaceutical Corp., San Diego, California

* Deceased.

John W. Levchuk, Ph.D. Adjunct Associate Professor, Department of Pharmaceutics, The University of Maryland, Baltimore, Maryland

Sol Motola, Ph.D.* Senior Director, Research and Development, Whitehall Laboratories, Hammonton, New Jersey

Robert S. Nase Manager, Quality Assurance and Microbiology, The West Company, Phoenixville, Pennsylvania

Robert J. Nash, Ph.D. West Chester University, West Chester, Pennsylvania

Leif E. Olsen Director, Regulatory Affairs and Quality Assurance, Regulatory affairs Department, Whittaker Bioproducts, Inc., Walkersville, Maryland

Edward J. Smith, Ph.D. Vice President, Health Care Group, The West Company, Phoenixville, Pennsylvania

Salvatore J. Turco, Pharm. D. School of Pharmacy, Temple University, Philadelphia, Pennsylvania

Yu-Chang John Wang, Ph.D. Director, Pharmaceutical Research and Development, California Biotechnology, Inc., Mountain View, California

Charles H. White Director, Research & Development, Thermoplastics, The West Company, Phoenixville, Pennsylvania

*Current affiliation: Wyeth-Ayerst Laboratories, Radnor, Pennsylvania

Contents of Pharmaceutical Dosage Forms: Parenteral Medications, Second Edition, Revised and Expanded, Volumes 2 and 3

edited by Kenneth E. Avis, Herbert A. Lieberman, and Leon Lachman

VOLUME 2

1. The Processing of Small Volume Parenterals and Related Sterile Products, *Richard J. Harwood, Joel Benton Portnoff, and Edward William Sunbery*
2. Factors Involved in Manufacturing Large Volume Parenterals, *Michael J. Groves and Karen Malik*
3. Freeze Drying: Principles and Practice, *Steven L. Nail and Larry A. Gatlin*
4. Environmental Factors in the Design Considerations for a Parenteral Production Facility, *A. Michael Keller and Howard Lange*
5. Biopharmaceutical Manufacturing Facility Design, *Robert Del Ciello*
6. Personnel: The Key Factor in Clean Room Operations, *Cecelia J. Luna*
7. Environmental Control in Parenteral Drug Manufacturing, *Franco DeVecchi*
8. Industrial Sterilization: A Review of Current Principles and Practices, *Frank J. Marino*
9. Formulation and Development of Ophthalmic Preparations, *K. M. Bapatla, R. Lambert, R. Hackett, and O. J. Lorenzetti*

VOLUME 3

1. Quality Assurance, *Samir Hanna*

2. Records and Reports, *David C. Fry and Karl L. Hofmann*
3. Particulate Matter, *Patrick P. DeLuca and Julius Z. Knapp*
4. Validation of Sterilization Processes and Sterile Products, *James Agalloco and James Akers*
5. Federal Regulation of Parenterals, *Terry Munson*
6. The Audit Process, *Ronald F. Tetzlaff*
7. Medical Devices: Design, Manufacture, and Quality Control, *David H. Wayt*
8. Quality Assurance for Medical Devices, *Carl W. Bruch*
9. Regulatory and GMP Considerations for Medical Devices, *Larry R. Pilot*

Contents of Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1–3

edited by Herbert A. Lieberman, Leon Lachman, and Joseph B. Schwartz

VOLUME 1

1. Preformulation Testing, *Deodatt A. Wadke and Harold Jacobson*
2. Tablet Formulation and Design, *Gilbert S. Banker, Garnet E. Peck, and George J. Baley*
3. Compressed Tablets, *Bhogi B. Sheth, Fred J. Bandelin, and Ralph F. Shangraw*
4. Compression-Coated and Layer Tablets, *William C. Gunsel*
5. Effervescent Tablets, *Raymond Mohrle*
6. Special Tablets: Sublingual and Buccal Tablets, *James W. Conine and Michael J. Pikal*
7. Chewable Tablets, *Jahan B. Daruwala*
8. Medicated Lozenges, *David Peters*

VOLUME 2

1. Mixing, *Russell J. Lantz, Jr. and Joseph B. Schwartz*
2. Drying, *Michael A. Zoglio and Jens T. Carstensen*
3. Size Reduction, *Russell J. Lantz, Jr.*

4. Compression, *Eugene L. Parrott*
5. Granulation and Tablet Characteristics, *Dale E. Fonner, Neil R. Anderson, and Gilbert S. Banker*
6. Bioavailability in Tablet Technology, *James W. McGinity, Salomon A. Stavchansky, and Alfred Martin*
7. Pharmaceutical Tablet Compression Tooling, *George F. Loeffler*

VOLUME 3

1. Principles of Improved Tablet Production System Design, *Neil R. Anderson, Gilbert S. Banker, and Garnet E. Peck*
2. Pan Coating of Tablets and Granules, *Stuart C. Porter, Charles H. Bruno, and Gerald J. Jackson*
3. Particle-Coating Methods, *Dale E. Wurster*
4. Sustained Drug Release from Tablets and Particles through Coating, *Joseph M. Conrad and Joseph R. Robinson*
5. The Pharmaceutical Pilot Plant, *Charles I. Jarowski*
6. Tablet Production, *Charles T. Lay and Frank W. Burans*
7. Stability/Kinetics, *Samir A. Hanna*
8. Quality Assurance, *Samir A. Hanna*

Contents of Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1 and 2

edited by Herbert A. Lieberman, Martin M. Rieger, and Gilbert S. Banker

VOLUME 1

1. Introduction, *Norman Weiner*
2. Theory of Suspensions, *Michael J. Falkowicz*
3. Theory of Emulsions, *Stig E. Friberg, Lisa B. Goldsmith, and Martha L. Hilton*
4. Theory of Colloids, *John Vanderhoff and Mohamed S. El-Aasser*
5. Pharmaceutical Suspensions, *Robert A. Nash*
6. Pharmaceutical Emulsions, *Bernard Idson*
7. Specialized Pharmaceutical Emulsions, *Morton Rosoff*
8. Surfactants, *Martin M. Rieger*
9. Rheology of Dispersed Systems, *Donald E. Deem*
10. Experimental Design, Modeling, and Optimization Strategies for Product and Process Development, *Robert M. Franz, Jeffrey E. Browne, and Allen R. Lewis*

VOLUME 2

1. Processing of Disperse Systems on a Production and Pilot Level, *Roy Scott*
2. Preservation of Dispersed Systems, *Harun Takruri and Claude B. Anger*
3. Bioavailability of Disperse Dosage Forms, *R. D. Schoenwald and D. R. Flanagan*
4. Viscosity-Imparting Agents in Disperse Systems, *Daniel A. Alderman and Joel Zatz*
5. Antacids and Clay Products, *Richard Harwood*
6. Internal Suspensions, *Clyde M. Ofner III, Roger L. Schnaare, and Joseph B. Schwartz*
7. Topical Suspensions, *N. H. Bhargava and Daniel W. Nicolai*
8. Reconstitutable Suspensions, *Clyde M. Ofner III, Roger L. Schnaare, and Joseph B. Schwartz*
9. Emulsions and Microemulsions, *L. H. Block*
10. Injectable Emulsions and Suspensions, *Joe Bruce Boyett and Craig William Davis*
11. Aerosol Suspensions and Emulsions, *John J. Sciarra*
12. Ophthalmic Ointment Suspensions, *Chris Bapatla*
13. Gels, *Joel L. Zatz, Joseph P. Berry, and Daniel A. Alderman*
14. Tooth Pastes, *David Garlen*
15. Suppositories, *Marion F. Gold*
16. Sticks, *Jack Margres*
17. Liposomes, *Norman Weiner*
18. Regulatory Affairs, *John Tomaszewski*
19. Quality Assurance, *Samir A. Hanna*

Contents

Preface	iii
Contributors	xi
Contents of Pharmaceutical Dosage Forms: Parenteral Medications, Second Edition, Revised and Expanded, Volumes 2 and 3	xiii
Contents of Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1-3	xv
Contents of Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1 and 2	xvii
 Chapter 1 The Parenteral Dosage Form and Its Historical Development	 1
<i>Kenneth E. Avis</i>	
I. The Dosage Form	1
II. History of Parenteral Medications	4
Appendix A: Glossary of Terms	12
Appendix B: Highlights in the History of Parenteral Medications	14
References	15
 Chapter 2 Parenteral Drug Administration: Routes, Precautions, Problems, Complications, and Drug Delivery Systems	 17
<i>Richard J. Duma, Michael J. Akers, and Salvatore J. Turco</i>	
Introduction	17
I. General Indications for Parenteral Administration of Drugs	18
II. Pharmaceutical Factors Affecting Parenteral Administration	19
III. Specific Routes of Administration	21
IV. Distribution of Parenterally Administered Agents	39

	V. Precautions, Problems, Hazards, and Complications Associated with Parenteral Drug Administration	41
	VI. Methods and Devices for Drug Delivery Systems	49
	VII. Summary	56
	References	57
Chapter 3	Biopharmaceutics of Injectable Medications	59
	<i>Sol Motola</i>	
	I. Introduction	59
	II. Physicochemical and Physiological Factors Affecting Drug Absorption by Injection: An Overview	60
	III. Application of Pharmacokinetics to Biopharmaceutic Investigations: Pharmacokinetic Models	77
	IV. Examples of Biopharmaceutic/Pharmacokinetic Principles	98
	V. Regulatory Considerations for Bioequivalence Studies	108
	VI. Bioequivalence Study of Two Injectable Forms of the Same Drug	109
	VII. Summary	111
	References	112
Chapter 4	Preformulation Research of Parenteral Medications	115
	<i>Sol Motola and Shreeram N. Agharkar</i>	
	I. Introduction	115
	II. Drug Substance Physicochemical Properties	116
	III. Accelerated Stability Evaluation	140
	IV. General Modes of Drug Degradation	150
	V. Preformulation Studies for Proteins and Peptides	154
	VI. Preformulation Screening of Parenteral Packaging Components	158
	VII. Summary	163
	VIII. Preformulation Worksheet	163
	References	169
Chapter 5	Formulation of Small Volume Parenterals	173
	<i>Patrick P. DeLuca and James C. Boylan</i>	
	I. Introduction	173
	II. Formulation Principles	174
	III. Container Effects on Formulation	227
	IV. Stability Evaluation	234
	V. Process Effects	244
	References	245

Chapter 6	Formulation of Large Volume Parenterals	249
	<i>Levit J. Demorest and Jeffrey G. Hamilton</i>	
	I. Introduction	249
	II. Concepts of Formulation	250
	III. Formulation Development	273
	IV. Solution Quality	280
	V. Summary	281
	References	281
Chapter 7	Parenteral Products of Peptides and Proteins	283
	<i>Yu-Chang John Wang</i>	
	I. Introduction	283
	II. Characteristics of Proteins and Peptides	284
	III. Formulation Principles	302
	IV. Compatibility with Packaging Components and Infusion Sets	310
	V. Formulation of Market Products	312
	References	317
Chapter 8	Sterile Diagnostics	321
	<i>Leif E. Olsen</i>	
	I. Introduction	321
	II. Diagnostic Products Defined	321
	III. Sterile Diagnostics	322
	IV. Definitions	325
	V. Aseptic Manufacturing Considerations	330
	VI. Validation Program	351
	VII. Conclusion	359
	References	359
Chapter 9	Glass Containers for Parenterals	361
	<i>R. Paul Abendroth and Robert N. Clark</i>	
	I. Introduction	361
	II. The Nature of Glass	361
	III. United States Pharmacopeia Glassware Classifications	362
	IV. The Manufacture of Glass Containers	369
	V. Chemical Performance	375
	VI. Mechanical Performance	380
	VII. The Container and Closure as a System	380
	VIII. Quality Assurance	382
	References	384